Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib plus rituximab for anti-MAG IgM MGUS polyneuropathy
NL-OMON59463Phase 2Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib and rituximab in anti-myelin-associated glycoprotein neuropathy and monoclonal gammopathy of undetermined significance (MGUS), sponsored by University Medical Center Utrecht. Primary endpoints: Neurological improvement by INCAT disability score, Adverse events and 2 more. Started Mar 2024; status: recruiting.
02
Drugs
zanubrutinibrituximab
03
Conditions
anti-myelin-associated glycoprotein neuropathymonoclonal gammopathy of undetermined significance (MGUS)
Beyond the preview
Go deeper on NL-OMON59463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59463.